Search results
Results from the WOW.Com Content Network
This is a list of adverse effects of the antidepressant trazodone, ... Bladder pain; Urinary incontinence; Gait disturbance; Reflux oesophagitis; Dry eye; Eye pain;
Trazodone, sold under many brand names, [1] is an antidepressant medication [20] used to treat major depressive disorder, anxiety disorders, and insomnia. [20] It is a phenylpiperazine compound of the serotonin antagonist and reuptake inhibitor (SARI) class.
The scarring of the small blood vessels, called capillary sclerosis, is the initial lesion of analgesic nephropathy. [7] Found in the renal pelvis, ureter, and capillaries supplying the nephrons, capillary sclerosis is thought to lead to renal papillary necrosis and, in turn, chronic interstitial nephritis.
Niaprazine (Nopron) – a drug related to this group but does not inhibit the reuptake of serotonin or the other monoamines. Medifoxamine (Clédial, Gerdaxyl) – could perhaps technically be said to belong to this group, as it is a serotonin–dopamine reuptake inhibitor and 5-HT 2A and 5-HT 2C receptor antagonist, but not grouped as such. [1]
Stelazine (trifluoperazine) – an antipsychotic used in the treatment of psychotic disorders, anxiety, and nausea caused by chemotherapy [2] Strattera (atomoxetine) – a non-stimulant medication used to treat ADHD; Suboxone (buprenorphine/naloxone) - a partial opioid agonist used in the treatment of opioid use disorder
In addition, due to their blockade of certain serotonin receptors, serotonergic neurotransmission is not facilitated in unwanted areas, which prevents the incidence of many side effects often associated with selective serotonin reuptake inhibitor (SSRI) antidepressants; [1] [3] hence, in part, the "specific serotonergic" label of NaSSAs. [2]
Vilazodone acts as a serotonin reuptake inhibitor (IC 50 = 2.1 nM; K i = 0.1 nM) and 5-HT 1A receptor partial agonist (IC 50 = 0.2 nM; IA = ~60–70%). [ 14 ] [ 26 ] It has negligible affinity for other serotonin receptors such as 5-HT 1D , 5-HT 2A , and 5-HT 2C , [ 26 ] [ 27 ] as well as the norepinephrine and dopamine transporters (K i = 56 ...
Treatment is typically with a catheter either through the urethra or lower abdomen. [1] [3] Other treatments may include medication to decrease the size of the prostate, urethral dilation, a urethral stent, or surgery. [1] Males are more often affected than females. [1] In males over the age of 40 about 6 per 1,000 are affected a year. [1]